On August 29, 2018 Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported it will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Heat Biologics, AUG 29, 2018, https://ir.heatbio.com/news/detail/607/heat-biologics-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference-in-new-york-city [SID1234529118]). The conference is being held on September 4-6, 2018 at The St. Regis New York in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jeff Wolf, Founder and Chief Executive Officer of Heat Biologics, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: 20th Annual Rodman & Renshaw Global Investment Conference
Date: Wednesday, September 5, 2018
Time: 4:40-5:05 PM (Eastern Time)
Location: Louis XVI B; The St. Regis New York
If you are unable to attend and would like to view the Company’s live webcast, please click on the following link (View Source).